Irwin Naturals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 25, 2023 at 03:21 pm EDT
Share
Irwin Naturals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 22.13 million compared to USD 21.81 million a year ago. Net loss was USD 5.32 million compared to net income of USD 0.039 million a year ago. Basic loss per share from continuing operations was USD 1.57 compared to basic earnings per share from continuing operations of USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 1.57.
For the six months, sales was USD 44.64 million compared to USD 44.4 million a year ago. Net loss was USD 12.95 million compared to net income of USD 1.34 million a year ago. Basic loss per share from continuing operations was USD 3.84 compared to basic earnings per share from continuing operations of USD 1.12 a year ago. Diluted loss per share from continuing operations was USD 3.84.
Irwin Naturals Inc. (Irwin) is a nutraceutical company. The Company is engaged in distributing cannabidiol (CBD) products in mass-market and health food chain stores across the United States. Irwin's portfolio of herbal products is available in more than 100,000 retail doors across North America. The Company's full range of Vitamin, CBD, and Supplements features over 100 products, created to address mood and brain function, better sleep, sports performance, sexual health, immune support, weight management, women's health and men's health. The Company's ketamine clinic, Emergence, is an infusion clinic that offers intravenous (IV) ketamine for the treatment of depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), anxiety, bipolar disorder, migraines, and multiple chronic pain conditions such as complex regional pain syndrome (CRPS), reflex sympathetic dystrophy (RSD) and fibromyalgia.
IRWIN NATURALS INC. 
